Study on the ineffective platelet transfusion in patients with hematologic malignancies during myelosuppression
10.3760/cma.j.issn.1009-9921.2020.01.009
- VernacularTitle: 恶性血液病患者骨髓抑制期血小板无效输注的研究
- Author:
Xiaoying HUA
1
;
Biao WANG
1
;
Wei WU
1
;
Zhimin SHANGGUAN
1
;
Liang TANG
1
Author Information
1. Department of Blood Transfusion, the First People's Hospital of Changzhou, the Third Affiliated Hospital of Soochow University, Changzhou 213003, China
- Publication Type:Journal Article
- Keywords:
Hematologic neoplasms;
Myelosuppression;
Platelet transfusion;
Medical futility
- From:
Journal of Leukemia & Lymphoma
2020;29(1):41-44
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the causes of ineffective platelet transfusion in patients with hematologic malignancies during myelosuppression and the therapeutic effect of rituximab.
Methods:A total of 180 patients with different hematologic malignancies in the First People's Hospital of Changzhou from January 2017 to December 2018 were selected. And the incidence of ineffective platelet transfusion during myelosuppression was observed. The changes of T and B lymphocyte subgroups and platelet counts before and after rituximab therapy in acute leukemia patients with platelet antibody-positive were compared, and the incidence of ineffective platelet transfusion with different platelet suspensions was analyzed.
Results:The ineffective platelet transfusion was observed in 45 of 180 patients (25.0%) during myelosuppression, including 30 (27.8%) of 108 patients with acute leukemia, 10 (23.3%) of 43 patients with myelodysplastic syndrome, 2 (13.3%) of 15 patients with malignant lymphoma, and 3 (21.4%) of 14 patients with multiple myeloma. The incidence of ineffective platelet transfusion in patients transfused with irradiated leukocyte depleted apheresis platelets (17.0%, 16/94) was lower than that in those with apheresis platelets (33.7%, 29/86), and the difference was statistically significant (χ2 = 6.68, P = 0.01). In 8 acute leukemia patients with platelet antibody-positive and the ineffective platelet transfusion after rituximab therapy, the increase of platelet count was observed in 5 patients. The differences of levels of CD19, CD20, CD4 and platelet count before and after treatment with rituximab were statistically significant (all P < 0.05).
Conclusions:The incidence of ineffective platelet transfusion is the highest in acute leukemia patients. Transfusion of human leukocyte antigen-matched platelets can improve the effect of platelet transfusion. Rituximab is effective in the ineffective platelets transfusion caused by immune factors. The incidence of ineffective platelet transfusion in irradiated leukocyte depleted apheresis platelets is lower compared with that in apheresis platelets.
